Trastuzumab for metastatic breast cancer: Real world outcomes from an Australian whole-of-population cohort (2001-2016).
暂无分享,去创建一个
Christine Y. Lu | B. Kiely | N. Houssami | R. Ward | S. Pearson | S. Lord | B. Daniels | R. Ward | Sarah J. Lord | Sallie-Anne Pearson | Benjamin Daniels
[1] W. Cheung,et al. Pertuzumab and Trastuzumab Emtansine for Human Epidermal Growth Factor Receptor-2–Positive Metastatic Breast Cancer: Contemporary Population-Based Outcomes , 2019, Breast cancer : basic and clinical research.
[2] B. Kiely,et al. Trastuzumab use in older patients with HER2-positive metastatic breast cancer: outcomes and treatment patterns in a whole-of-population Australian cohort (2003–2015) , 2019, BMC Cancer.
[3] A. Pandiella,et al. Paclitaxel-Trastuzumab Mixed Nanovehicle to Target HER2-Overexpressing Tumors , 2019, Nanomaterials.
[4] B. Kiely,et al. Accentuating the Positive: Do Trials Give Unrealistic Expectations of Long-Term Survival? , 2019, JNCI cancer spectrum.
[5] G. Minuti,et al. Patterns of Care and Clinical Outcomes of HER2‐positive Metastatic Breast Cancer Patients With Newly Diagnosed Stage IV or Recurrent Disease Undergoing First‐line Trastuzumab‐based Therapy: A Multicenter Retrospective Cohort Study , 2017, Clinical breast cancer.
[6] Gary H Lyman,et al. Untapped Potential of Observational Research to Inform Clinical Decision Making: American Society of Clinical Oncology Research Statement. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] Christine Y. Lu,et al. Use and outcomes of targeted therapies in early and metastatic HER2-positive breast cancer in Australia: protocol detailing observations in a whole of population cohort , 2017, BMJ Open.
[8] P. Wise. Cancer drugs, survival, and ethics , 2016, British Medical Journal.
[9] R. Viney,et al. Real-World Evidence: A Comparison of the Australian Herceptin Program and Clinical Trials of Trastuzumab for HER2-Positive Metastatic Breast Cancer , 2016, PharmacoEconomics.
[10] H. Bitterman,et al. Second-Line Treatment of Her2-Positive Metastatic Breast Cancer: Trastuzumab beyond Progression or Lapatinib? A Population Based Cohort Study , 2015, PloS one.
[11] G. Minuti,et al. Patterns of Care and Clinical Outcomes of First-Line Trastuzumab-Based Therapy in HER2-Positive Metastatic Breast Cancer Patients Relapsing After (Neo)Adjuvant Trastuzumab: An Italian Multicenter Retrospective Cohort Study. , 2015, The oncologist.
[12] Sung-Bae Kim,et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. , 2015, The New England journal of medicine.
[13] G. Fasola,et al. Measures of outcome in metastatic breast cancer: insights from a real-world scenario. , 2014, The oncologist.
[14] E. Wu,et al. Comparison of treatment patterns and economic outcomes in metastatic breast cancer patients initiated on trastuzumab versus lapatinib: a retrospective analysis , 2014, SpringerPlus.
[15] H. Rugo,et al. Treatment patterns and clinical outcomes for patients with de novo versus recurrent HER2-positive metastatic breast cancer , 2014, Breast Cancer Research and Treatment.
[16] Yu Shen,et al. First do no harm: population-based study shows non-evidence-based trastuzumab prescription may harm elderly women with breast cancer , 2014, Breast Cancer Research and Treatment.
[17] C. Isaacs,et al. Risk of cardiovascular adverse events from trastuzumab (Herceptin®) in elderly persons with breast cancer: a population-based study , 2014, Breast Cancer Research and Treatment.
[18] Christine Y. Lu,et al. Trastuzumab therapy in Australia: which patients with HER2+ metastatic breast cancer are assessed for cardiac function? , 2013, Breast.
[19] C. Y. Lu,et al. Positive spillover effects of prescribing requirements: increased cardiac testing in patients treated with trastuzumab for HER2+ metastatic breast cancer , 2012, Internal medicine journal.
[20] Sabine Tejpar,et al. Molecular and clinical determinants of survival following relapse after treatment of stage ii-iii colon cancer (cc). results of the translational study on the petacc 3-eortc 40993-sakk 60-00 trial , 2010 .
[21] M. Rawlins. De testimonio: on the evidence for decisions about the use of therapeutic interventions , 2008, The Lancet.
[22] J. Avorn. In defense of pharmacoepidemiology--embracing the yin and yang of drug research. , 2007, The New England journal of medicine.
[23] R. Ward,et al. Trastuzumab and metastatic breast cancer: trastuzumab use in Australia--monitoring the effect of an expensive medicine access program. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] C. Hudis,et al. Cardiac dysfunction in the trastuzumab clinical trials experience. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] T. Fleming,et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.
[26] C. Coltman,et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. , 1999, The New England journal of medicine.
[27] A. Tutt,et al. 3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3). , 2017, Breast.
[28] C. la Vecchia,et al. Trastuzumab for HER2+ metastatic breast cancer in clinical practice: Cardiotoxicity and overall survival. , 2016, European journal of cancer.
[29] R Core Team,et al. R: A language and environment for statistical computing. , 2014 .
[30] J. Thigpen,et al. Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer , 2012 .